Metastatix is a pharmaceutical company built on a single idea: Developing and commercializing effective small-molecule drug therapies that are easy to take and have the fewest possible side effects. Using rational drug design, we have created a portfolio of potent and structurally novel antagonists to multiple chemokine receptors. Our initail focus has been on the CXCR4 receptor, a critical mediator of cellular and chemical trafficking. These antagonists show efficacy in validated models of: